Cidara Therapeutics

Our CEO, Jeffrey Stein, Ph.D., was featured in the latest Scrip Asks issue discussing the need for innovative therapies to effectively treat multiple #influenza strains, including those with pandemic potential like #H5N1. Read more: https://lnkd.in/dSyX8Mmu

We are pleased to announce the appointment of Frank Karbe as Chief Financial Officer. He brings over 25 years of experience as a strategic financial leader in the biopharma industry, scaling companies from early stage to commercialization. We look forward to his contributions to Cidara. Read more about Mr. Karbe’s background here: https://lnkd.in/eUJB87Mj

Congratulations to our board member, Bonnie L. Bassler, Ph.D., for receiving the National Medal of Science from President Biden for her outstanding contributions to science. We’re proud to have such an incredible scientific leader on our team. Read more: https://lnkd.in/ewhj9Fc9

We’re pleased to announce we’ve reached full planned enrollment of 5,000 subjects in our Phase 2b NAVIGATE #ClinicalTrial across sites in the US and UK. Read more about the trial and this important milestone here: https://lnkd.in/gTridsBB

Today we announced a $105M private placement led by Venrock Healthcare Capital Partners, with significant participation by new and existing life-sciences focused investors. Read more here: https://lnkd.in/einV_AAS

Learn more about our long-acting antiviral drug-Fc conjugate (DFC) for #influenza, and the journey that led to our ongoing Phase 2b clinical trial, in this recent article from BioProcess Online: https://lnkd.in/gA2n-mTk

We’re presenting at this year’s IDWeek! Our two presentations will highlight clinical data on the safety, pharmacokinetics and prophylactic activity of our drug-Fc conjugate (DFC) asset for #influenza. Read more: https://lnkd.in/ewXxRHRn #IDWeek2024

Today we announced two presentations highlighting data on our #influenza drug-Fc conjugate (DFC) candidate at the 2024 OPTIONS XII conference in Brisbane, Australia. Read here for more information on our oral and poster presentations: https://lnkd.in/gtbxJp3J

Today we announced the first subjects dosed in our Phase 2b NAVIGATE trial to evaluate the efficacy and safety of our #flu drug-Fc conjugate (DFC) for the pre-exposure prophylaxis of influenza during the current flu season. Read more here: https://lnkd.in/gTB7i2Tb

We’re pleased to announce the appointment of Rick Bright, Ph.D., Philip Krause, MD, Mario Barro, Ph.D., and Frederick G. Hayden, MD, FACP to our Scientific Advisory Board. Learn more about these infectious disease experts and how they will help guide us as we continue to advance our drug-Fc conjugate for influenza: https://lnkd.in/gYyGMWiN